Johnson & Johnson (NYSE:JNJ) Stock Holdings Reduced by Valley Wealth Managers Inc.

Valley Wealth Managers Inc. lowered its stake in Johnson & Johnson (NYSE:JNJ) by 0.3% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 22,907 shares of the company’s stock after selling 79 shares during the period. Valley Wealth Managers Inc.’s holdings in Johnson & Johnson were worth $3,712,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. China Universal Asset Management Co. Ltd. acquired a new position in Johnson & Johnson during the 1st quarter worth $765,000. Empowered Funds LLC grew its holdings in shares of Johnson & Johnson by 46.7% in the 1st quarter. Empowered Funds LLC now owns 101,237 shares of the company’s stock valued at $16,015,000 after acquiring an additional 32,244 shares in the last quarter. Edmond DE Rothschild Holding S.A. grew its holdings in shares of Johnson & Johnson by 2.7% in the 1st quarter. Edmond DE Rothschild Holding S.A. now owns 65,007 shares of the company’s stock valued at $10,283,000 after acquiring an additional 1,689 shares in the last quarter. Schneider Downs Wealth Management Advisors LP lifted its stake in Johnson & Johnson by 85.8% in the 1st quarter. Schneider Downs Wealth Management Advisors LP now owns 3,818 shares of the company’s stock valued at $604,000 after purchasing an additional 1,763 shares during the last quarter. Finally, Barings LLC acquired a new stake in Johnson & Johnson in the 1st quarter valued at about $217,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Activity

In related news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the transaction, the vice president now directly owns 18,973 shares of the company’s stock, valued at $3,131,683.38. This trade represents a 22.90 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on JNJ shares. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Morgan Stanley lifted their price objective on shares of Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. Sanford C. Bernstein lifted their price objective on shares of Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Wolfe Research started coverage on shares of Johnson & Johnson in a research note on Friday. They set an “outperform” rating and a $190.00 target price on the stock. Finally, Wells Fargo & Company boosted their price objective on shares of Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 16th. Seven research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and an average price target of $175.94.

Johnson & Johnson Trading Up 0.3 %

Shares of JNJ stock traded up $0.43 on Friday, hitting $152.30. 1,314,792 shares of the company’s stock traded hands, compared to its average volume of 6,972,152. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. Johnson & Johnson has a one year low of $143.13 and a one year high of $168.85. The company’s fifty day simple moving average is $161.56 and its 200 day simple moving average is $155.97. The stock has a market capitalization of $366.68 billion, a price-to-earnings ratio of 22.04, a P/E/G ratio of 2.72 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. The business had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The company’s revenue was up 5.2% on a year-over-year basis. During the same quarter last year, the firm earned $2.66 EPS. Equities analysts forecast that Johnson & Johnson will post 9.93 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be issued a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.26%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 71.78%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.